Latest Commercialization News

Gold Hydrogen Limited confirms full settlement of a strategic investment by three Japanese industry players, setting the stage for an ambitious 2025 work program at its Ramsay Project focused on natural hydrogen and helium exploration.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

Elsight Limited reports unprecedented revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market demand. The company is on track to achieve profitability in the second half of the year.

AnteoTech has signed a binding Term Sheet with US-based Black Diamond Structures to jointly develop and commercialise an advanced battery additive combining their proprietary technologies, targeting improved lithium-ion battery anodes with higher silicon content.

RBR Group stands uniquely positioned as the only ASX-listed company directly linked to Mozambique’s LNG megaprojects, gearing up for a sector revival and broader African growth.

RareX Limited has successfully raised A$2 million through a share placement at a premium, positioning itself to advance exploration and development across key rare earths projects in Australia and Kenya.

Tivan Limited and Sumitomo Corporation have signed a Memorandum of Understanding to jointly develop the high-grade Sandover Fluorite Project in Australia's Northern Territory, marking a significant step in Australia's critical minerals sector.

Cleo Diagnostics reports steady progress in its ovarian cancer diagnostic test development, with clinical trial recruitment on track and strategic access to major biobanks enhancing its regulatory pathway.

Elixir Energy has advanced its strategic plan in Queensland’s Taroom Trough, appointing a new COO, initiating a major cost reduction, and preparing to drill key exploration and appraisal wells that could unlock significant gas resources.

PainChek has completed its final FDA submission for the PainChek Adult App, targeting the US long-term care market with a potential $100 million annual opportunity. A regulatory decision is expected within 75 days, setting the stage for rapid commercialisation.

Norwood Systems delivered its strongest quarter yet with record cash inflows, significant debt reduction, and expanding global partnerships, setting a robust foundation for FY2026.

PYC Therapeutics reports solid progress across its four RNA therapeutic programs targeting genetic diseases, backed by a strong cash position extending runway beyond 2027.